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Background: The subcellular localization and cellular functions of EFA6R are unknown.
Results: EFA6R requires dual targeting through the PH and CC domains to localize to the plasma membrane and function as a
GEF.
Conclusion: Plasma membrane-localized EFA6R stimulates actin reorganization through ARF6 activation.
Significance: This study provides insight into the localization and cellular functions of EFA6R.
ADP-ribosylation factor 6 (ARF6) small GTPase regulates
membrane trafficking and cytoskeleton rearrangements at the
plasma membrane (PM) by cycling between the GTP-bound
active and GDP-bound inactive conformations. Guanine nucle-
otide exchange factors (GEFs) activate ARF6. The exchange fac-
tor for ARF6 (EFA6) R has been identified as a biomarker for
ovarian cancer. EFA6R shares the catalytic Sec7, pleckstrin
homology (PH), and coiled coil (CC) domains of the other EFA6
family GEFs. Here we report the functional characterization of
EFA6R. Endogenous EFA6R was present in the plasma mem-
brane fraction. The exogenously expressed FLAG- and GFP-
tagged EFA6R were targeted to the PM. In vitro, GFP-EFA6R
associated weakly but preferentially with phosphatidylinositol
4,5-bisphosphate (PIP2) through the PH domain. EFA6R
required both its PH and CC domains localized at the C termi-
nus to target the PM. Consistent with this, EFA6R lacking the CC
domain (EFA6RCC) was released from the PM into the cytosol
upon PIP2 depletion, whereas EFA6R release from the PM
required both PIP2 depletion and actin destabilization. These
results suggest that thedual targetingvia thePHandCCdomains is
important for the PM localization of EFA6R. EFA6R specifically
catalyzed the GTP loading of ARF6 in mammalian cells. More-
over, EFA6R regulated ARF6 localization and thereby actin
stress fiber loss. The GEF activity of EFA6R was dependent on
the presence of the Sec7 domain. The PH and CC domains were
also required for the in vivoGEF activity of EFA6R but could be
functionally replaced by the CAAXmotif of K-Ras, suggesting a
role for these domains in the membrane targeting of EFA6R.
ADP-ribosylation factors (ARFs)2 are a family of Ras-related
small GTPases that are expressed abundantly in all eukaryotic
cells and some bacteria. Six ARF proteins (ARFs 1–6) are found
inmammals, althoughARF2 is absent in humans. ARFs 1–5 are
mainly localized to theGolgi and involved in intracellularmem-
brane trafficking (1). In contrast, ARF6 is localized to the
plasma membrane (PM) and endosomes where it regulates
membrane trafficking and actin cytoskeleton remodeling
events that are required for a wide variety of cellular processes
such as exocytosis, endocytosis, formation of neuronal axonal
branches and dendritic spines, and cell motility (2–4). Like
other small GTPases, ARFs act as binary switches by cycling
between inactive GDP-bound and active GTP-bound forms.
The active GTP-bound ARFs interact with downstream effec-
tors to mediate various cellular responses. The active/inactive
cycle of ARFs is tightly regulated by guanine nucleotide
exchange factors (GEFs) andGTPase-activating proteins. GEFs
activate ARFs by catalyzing the exchange of bound GDP for
GTP. GTPase-activating proteins inactivate ARFs by stimulat-
ing their GTPase activity for the hydrolysis of bound GTP to
GDP (5, 6).
ARF GEFs contain a conserved Sec7 catalytic domain, which
has facilitated the identification of these ARF regulators in
eukaryotes (7). There are more than 15mammalian ARF GEFs,
which have been classified into six families based on their
sequence similarities (8). The ARF substrate specificity, local-
ization, and function have not been determined formanyGEFs.
Because ARF1 and ARF6 have distinct subcellular localization,
it is believed that the specificity of GEFs toward their substrate
ARF isoform is dependent on their subcellular localization (9)
with ARF1 GEFs being localized to the Golgi and ARF6 GEFs
being found at the PMwhereGDP/GTP exchange onARF6 has
been shown to occur (10). Among the six families of ARFGEFs,
the EFA6, cytohesin, and brefeldin A-resistant ARF GEF
(BRAG) families of GEFs have been shown to activate ARF6 (5).
However, the cytohesins can also activate ARF1 in vitro and in* This work was supported by Biotechnology and Biological Sciences
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vivo (11, 12). In addition to the Sec7 domain, both EFA6 and
cytohesin family members contain a phosphatidylinositol (PI)-
binding pleckstrin homology (PH) domain and one or more
coiled coil (CC) domains, which may be important for protein-
protein interactions and in the case of the ARF6 GEF EFA6 is
involved in cytoskeletal rearrangements (13–15).
The EFA6 family comprises four mammalian members
(EFA6A–C and R), which show distinct tissue distribution at
the mRNA level. EFA6A and EFA6C are expressed predomi-
nantly in the brain, whereas EFA6B and EFA6R (also known as
EFA6D/HCA67/PSD3) are more widely expressed (16–18).
Although EFA6B mRNA is not expressed in the brain, EFA6A,
EFA6C, and EFA6R have been shown to exhibit distinct
regional distributions in the brain (18). These expression pro-
file studies suggest that each member of the EFA6 family may
have diverse physiological functions in different tissues. EFA6R
was originally identified by immunological screening of recom-
binant cDNA libraries obtained from hepatocellular carcinoma
samples and has since been shown to be up-regulated in colon
cancer and down-regulated in breast, prostate, glioblastoma,
and ovarian cancer (7, 14, 19–22). Moreover, analysis of genes
with extremely imbalanced expression in the chromosomal
regions associated with breast cancer metastasis has identified
EFA6R as a candidate metastasis suppressor gene (19).
Here we report further characterization of EFA6R by analy-
ses of its protein expression in various tissues and cell lines,
subcellular localization, ARF substrate specificity, and cellular
functions. We show that EFA6R was expressed ubiquitously
and functioned as a GEF for ARF6, but not ARF1, in vivo, and
that it was targeted to the PM via binding to PIP2 directly and
actin indirectly through its PH and CC domains, respectively.
We also show that EFA6Rwas involved in reorganization of the
actin cytoskeleton by activating ARF6.
EXPERIMENTAL PROCEDURES
Materials—The primary antibodies used were mouse anti-HA
HA11 (Covance), mouse anti-GFP (Roche Applied Science),
mouse anti-FLAG M2 (Sigma), mouse anti--tubulin (Sigma),
and mouse anti-epidermal growth factor receptor (Santa Cruz
Biotechnology). Rabbit anti-EFA6R antibody was produced
against a peptide representing the last 15 C-terminal amino
acids of EFA6R and affinity-purified by using the immunizing
peptide-coupled resin through a commercial vendor (Eurogen-
tec). Cy3- and Cy5-conjugated anti-mouse IgG (Jackson
ImmunoResearch Laboratories) secondary antibodies and
TRITC-conjugated phalloidin (Sigma) were used for immuno-
fluorescence. Horseradish peroxidase-conjugated anti-mouse
and anti-rabbit IgG (GEHealthcare) secondary antibodies were
used for immunoblotting. INSTA-Blot human tissues and
Mowiol were from Merck Millipore. All other chemicals were
from Sigma unless otherwise specified.
Plasmids—The full-length human EFA6R (isoform B) and its
deletion mutant cDNAs were amplified frommammalian gene
collection clone 104121 (Source Bioscience) by PCR usingHigh
Fidelity Taq DNA polymerase (Roche Applied Science) and
sequence-specific primers containing EcoRI (sense) and SalI
(antisense) restriction sites. The cDNAwas digestedwith EcoRI
and SalI and cloned into the same sites of pCMV-Tag2b (Strat-
agene) for expression as FLAG-tagged fusion protein and pEG-
FPC2 vector (Clontech) for expression as green fluorescent
protein (GFP)-tagged fusion protein in mammalian cells. The
EFA6RE134K mutant was generated using a QuikChange II site-
directed mutagenesis kit (Stratagene). The GFP-EFA6R and its
deletion mutants were targeted to membranes by attaching a
C-terminal CAAXmotif using PCRwith a 3-primer containing
the coding sequence for the CAAX motif from K-Ras (KDGK-
KKKKKSKTKCVIM) as described previously (23). The ARF6-
HA/pXS, ARF1-HA/pXS, ARF6T27N-HA/pXS, and ARF1T31N-
HA/pXS constructs were used to express ARF proteins with a
C-terminal hemagglutinin (HA) epitope tag in mammalian
cells (24). ARF6T44N-HA/pXS, GST-GGA3 protein binding
domain (PBD; amino acids 1–316), FLAG-EFA6A, and GFP-
EFA6A constructs have been described previously (25–28).
EFA6C cDNA was obtained by PCR amplification of mamma-
lian gene collection clone 45998, digested with EcoRI (sense)
and SalI (antisense), and cloned into the same sites of
pEGFP-C2 (Clontech) to obtain GFP-EFA6C construct. The
PLC1PH-GFP, mRFP-FKBP-5-ptase-dom (the 5-phosphatase
domain of human type IV 5-phosphatase enzyme fused to
FK506-binding protein 12-mRFP), and PM-FRB-CFP (the PM-
targeted FKBP12-rapamycin binding-CFP) constructs, kindly
provided by Dr. Tamas Balla (National Institutes of Health),
have been described previously (29).
siRNAOligonucleotides—HumanEFA6R siRNA1 (5-GCUAC-
UGAGUAACGAUGAA-3) and siRNA2 (5-GGAGAAAGCU-
AACGGAACA-3) duplexes were used. As a negative control,
an siRNA duplex consisting of a unique sequence that does not
have significant homology to any mammalian gene sequences
was used. Human ARF6 siRNA has been described previously
(27). The 21-nucleotide siRNA duplexes were synthesized by
Eurogentec.
Cell Culture and Transfection—HeLa and COS7 cells were
maintained in DMEM supplemented with 10% fetal calf serum
and antibiotics in a 37 °C, 5% CO2 incubator. Cells were trans-
fected with plasmids for 2 days using Genejuice (Novagen) or
siRNA for 3 days using INTERFERin (Polyplus Transfection)
according to themanufacturers’ instructions. For immunofluo-
rescence, cells were seeded onto sterile 13-mm glass coverslips
in 24-well plates 24 h before transfection. For ARF activation
assays, cells were seeded into either 6- or 10-cm tissue culture
dishes 24 h before transfection.
Cell Fractionation—Cells were harvested from a 10-cm plate
by scraping in 1 ml of ice-cold resuspension buffer (10 mM
Tris-HCl, pH 7.5, and 0.1 M sucrose with 1% mammalian pro-
tease inhibitor mixture) and lysed by passing 5–10 times
through a 26-gauge needle attached to a 1-ml syringe (30). Cell
lysate was centrifuged at 1000 g for 5min at 4 °C to obtain the
postnuclear supernatant. The postnuclear supernatant was
centrifuged at 100,000  g for 30 min at 4 °C to obtain the
cytosolic (supernatant) and membrane fractions (pellet). The
protein concentration of the cytosolic andmembrane fractions
was determined using the bicinchoninic acid (BCA) method.
Whole cell extracts and cytosolic andmembrane fractions were
subjected to immunoblotting to assess the levels of -tubulin (a
cytosolic protein), epidermal growth factor receptor (a mem-
brane protein), and EFA6R in each fraction.
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The plasma membrane fraction was prepared from HeLa
cells as described previously (31). Briefly, HeLa cells were incu-
bated with 0.1 mg/ml EZ-Link Sulfo-NHS-SS-Biotin (Pierce)
for 15min for cell surface biotinylation. Cells were then scraped
in ice-cold hypotonic buffer (10 mM HEPES, pH 7.5, 1.5 mM
MgCl2, and 10 mM KCl with 1% mammalian protease inhibitor
mixture) and lysed by using Dounce homogenization. Cell
lysates were centrifuged at 1000 g for 5 min at 4 °C to obtain
the postnuclear supernatant. After adjusting the KCl concen-
tration to 150 mM, the postnuclear supernatant was incubated
with streptavidin magnetic beads (Pierce) for 1 h at 4 °C. The
beads were washed with hypotonic buffer to obtain the plasma
membrane fraction or 1 M KCl and 0.1 M Na2CO3, pH 11.5 and
then hypotonic buffer to obtain the integral plasma membrane
fraction.
Immunoblotting—Protein samples were separated by SDS-
PAGE and transferred onto PVDF membrane (Whatman).
Blots were probed with primary antibody followed by the
appropriate HRP-conjugated secondary antibody and devel-
oped using ECL substrate (28, 32).
In Vitro PI Binding Assay—The in vitro PI binding assay was
performed as described previously (23). Briefly, COS7 cells
transfected for 2 days with GFP, GFP-tagged EFA6R or its
mutants, orGFP-PLCPHwere treatedwith lysis buffer (10mM
HEPES, pH 7.4, 150 mM NaCl, 0.5% Nonidet P-40, and 5 mM
dithiothreitol) containing 1% mammalian protease inhibitor
mixture. Cell lysates were incubated with avidin beads (Pierce)
or avidin beads coupled to biotinylated PI (Cell Signaling Tech-
nology) for 2 h at 4 °C. For competition binding experiments,
biotinylated PI 3,4-P2 beads were incubated with the cell lysate
in the presence of 1 nM to 10Mnon-biotinylatedwater-soluble
(diC8) PIs (Cell Signaling Technology). Beads were washed
twice with lysis buffer, and bound proteins were eluted by boil-
ing in SDS-PAGE sample buffer. Proteins were then separated
by SDS-PAGE and transferred to PVDF membrane. The blots
were probed with an anti-GFP antibody, and the relative inten-
sity of detected bands was determined by scanning and analyz-
ing using ImageJ software.
GST-GGA3 PBD Pulldown Assay—ARF6 activation was
assessed by using the GST-GGA3 PBD pulldown assay as
described previously (33). After transfection for 48 h, cells were
serum-starved for 2 h and lysed in ice-cold modified radioim-
mune precipitation assay buffer (50 mM Tris, pH 7.5, 150 mM
NaCl, 10 mM MgCl2, 1% Triton X-100, 0.5% sodium deoxy-
cholate, 0.1% SDS, and 1% mammalian protease inhibitor mix-
ture). Lysates were incubated for 2 h at 4 °C with 10 l of GST-
GGA3PBDbeads,whichwere prepared as described previously
(27, 28). The beads were washed three times with 1 ml of wash
buffer (50mMTris, pH 7.5, 150mMNaCl, 10mMMgCl2, and 1%
Triton X-100). Lysates not incubated with beads were used as
input controls. HA-tagged ARF6- or ARF1-GTP bound to the
beads and total ARF1 orARF6 in the inputswere determined by
immunoblotting using an anti-HAantibody.GFP,GFP-EFA6R,
and GFP-EFA6A expression in the inputs was assessed by
immunoblotting using an anti-GFP antibody. Immunoblots
were scanned, and the GTP-bound ARF6 precipitated with
GST-GGA3 PBD beads was normalized to total ARF6 levels in
the lysates to compare ARF6-GTP levels under different condi-
tions (34).
Ionomycin and Rapamycin Treatments—2 days after trans-
fection, cells were washed three times with PBS and stimulated
with either 10 M ionomycin (Tocris) for 5 min in Hanks’ bal-
anced salt solution or 100 nM rapamycin (LCLaboratories) for 3
min in PBS at 37 °C. Where indicated, the cells were treated
with cytochalasin D at 10 g/ml for 30 min before exposing to
ionomycin or rapamycin (30).
Immunofluorescence—Immunofluorescence was carried out
as described previously (35). Briefly, 2 days after transfection,
cells were serum-starved for 2 h and then fixed with 4% para-
formaldehyde for 15 min. Where required, cells were permea-
bilized with 0.2% Triton X-100 in PBS for 10 min, blocked in
blocking buffer (1% BSA and 0.1% Triton X-100 in PBS) for 30
min, and then incubated with an anti-HA mouse monoclonal
antibody diluted (1:500) in blocking buffer for 1 h. Cells were
washed three times with wash buffer (0.1% Triton X-100 in
PBS) and incubated in blocking buffer containing a 1:500 dilu-
tion of Cy3-conjugated anti-mouse antibody, 1:5000 dilution of
TRITC-phalloidin, or 1:500 dilution of Cy5-conjugated anti-
mouse antibody and 1:5000 dilution of TRITC-phalloidin for
1 h. Cells were then washed three times with wash buffer, and
the coverslips were mounted on glass microscopic slides with
mounting solution (0.1 M Tris-HCl, pH 8.5, 10% Mowiol, and
50% glycerol) containing 2.5% 1,4-diazabicyclo[2.2.2.]octane.
Immunofluorescence staining was visualized using a Zeiss
LSM710 confocal microscope. For quantification, the densito-
metric ratio of plasma membrane-localized EFA6R versus total
EFA6R was calculated using ImageJ software.
Data Analysis—The ImageJ program was used for densito-
metric analysis. Data were analyzed using the GraphPad Prism
program. Results are expressed as the mean  S.D. of three
experiments. Statistical significance was determined by one-
way or two-way analysis of variance where p  0.05 was con-
sidered as statistically not significant and p 0.01 (**) and p
0.001 (***) were considered as statistically significant. Confocal
images are representative of 190–200 transfected cells from
three independent experiments. Immunoblotting data are rep-
resentative of three separate experiments.
RESULTS
Domain Structure and Expression of EFA6R—EFA6R shares
59% amino acid identity to EFA6A and contains the same
domain structure as EFA6A: an N-terminal variable region fol-
lowed by a Sec7 domain, a PH domain, and a C-terminal CC
domain. In the Sec7 domain, EFA6R shows high identity to
EFA6A (66%), EFA6B (60%), and EFA6C (70%) (16). The
human gene for EFA6R is located on chromosome 8, position
8p22 (14). Two splice variants (isoforms A and B) have so far
been predicted through alternative splicing ofEFA6R that differ
fromeach other in length of theN-terminal variable region (Fig.
1A). However, the EFA6R isoform A domain structure is iden-
tical to that of isoform B. RT-PCR analysis by Sakagami et al.
(18) revealed that EFA6R mRNA is expressed ubiquitously in
mouse tissues, and therefore, we assessed EFA6R protein
expression in various human tissues and cell lines by immuno-
EFA6R Functions as an ARF6 GEF
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blotting. For this purpose, a rabbit polyclonal antibody was
raised against the last 15 C-terminal residues of EFA6R.
To verify antibody specificity, we performed immunoblot
analysis of extracts from cells overexpressing cytohesins 1–4,
EFA6A, EFA6C, and EFA6R fused with an N-terminal GFP tag
(Fig. 1B). This analysis confirmed that the EFA6R anti-peptide
antibody recognized an85-kDa protein only in cells express-
ingGFP-EFA6R. Cytohesins 1–4, EFA6A, and EFA6Cwere not
recognized by the EFA6R antibody, whereas an anti-GFP anti-
body detected all of the GFP-tagged ARF GEFs (indicating the
expression of all ARF GEFs). However, the 85-kDa protein was
not detected by anti-EFA6R antibody that had been preincu-
bated with the immunizing peptide (Fig. 1C). We also analyzed
whether the EFA6R antibody labels cells overexpressing GFP-
tagged EFA6R or EFA6A and compared the pattern of staining
with that observed with GFP fluorescence. In cells expressing
GFP-EFA6R, the EFA6R antibody staining pattern was identi-
cal to that observed with the GFP fluorescence (Fig. 1D).
However, in cells expressing GFP-EFA6A, anti-EFA6R anti-
body did not immunostain transfected cells (Fig. 1D), suggest-
ing that, although specific for EFA6R, the EFA6R antibody is
incapable of recognizing (low level) endogenous EFA6R by
immunostaining.
Having determined antibody specificity, EFA6R expression
was analyzed in human cells and tissues by immunoblotting
(Fig. 2, A and B). EFA6R was variably expressed in most tissues
and cell lines tested where it was detected predominantly as a
56-kDa protein (isoform B). This EFA6R isoform B expression
was abundant in liver, spleen, and testis; moderate in brain,
heart, and skeletal muscle; and low in small intestine, kidney,
lung, stomach, and ovary. Similarly, a major 56-kDa protein
band was detectable at relatively high levels in HeLa, COS7,
A549, andHEK293 cells. Moderate levels were expressed in the
other cell lines tested except in human neuroblastoma (SH-
SY5Y) and leukemic monocyte (THP-1) cell lines where stain-
ing was undetectable. These findings are consistent with obser-
vations that EFA6R is down-regulated in some cancers such as
ovarian cancer and glioblastoma (14, 21). Furthermore, the
56-kDaband intensitywas significantly reduced in the lysates of
cells transfected with EFA6R siRNA1 or siRNA2 but not with
eitherARF6 siRNA (positive control) or universal negative con-
trol siRNA (Fig. 2C), which confirms the expression of EFA6R
as a 56-kDa protein (isoform B).
To determine whether endogenous EFA6R was membrane-
bound in HeLa cells, we mechanically disrupted the cells and
assessed EFA6R expression in the cytosolic and membrane
fractions by immunoblotting. Indeed, over 90% of the EFA6R
was in the membrane fraction (Fig. 2D). However, the EFA6R
associated with the membrane fraction was incompletely solu-
bilized by treatment with 1% Triton-X-100, suggesting that it
may associate with the Triton-insoluble cytoskeleton (not
shown; see Fig. 5). Further analysis revealed the presence of
endogenous EFA6R in the plasma membrane fraction of HeLa
cells as non-integral membrane protein (Fig. 2E).
FIGURE 1. EFA6R domain structure and its antibody characterization. A, schematic representation of the domain structure of isoforms A and B of EFA6R.
Sec7, Sec7domain;PH, PHdomain;CC, coiled coilmotif;aa, amino acids.B, immunoblot (IB) analysis of the specificity of an anti-peptide EFA6R rabbit polyclonal
antibody. The lysates (5 g of protein/lane) of COS7 cells expressing GFP-tagged cytohesins 1–4, EFA6A, EFA6B, and EFA6R were separated by SDS-PAGE,
blotted onto PVDFmembrane, and probedwith an anti-GFP or an anti-EFA6R antibody. C, immunoblot (IB) analysis of the specificity of EFA6R antibody using
the immunizing peptide. The lysates (5g of protein/lane) of COS7 cells expressing GFP-EFA6R were separated by SDS-PAGE, blotted onto PVDFmembrane,
and probed with the anti-EFA6R antibody (lane I) or the anti-EFA6R antibody preincubated with the immunizing peptide (lane II). D, immunostaining of HeLa
cells transfectedwithGFP,GFP-EFA6R, orGFP-EFA6Ausing the anti-EFA6Rantibody. HeLa cells transfectedwithGFPor theGFP-EFA6RorGFP-EFA6Aconstruct
for 2 days were fixed, stained with the anti-EFA6R antibody, and visualized by a confocal microscopy.
EFA6R Functions as an ARF6 GEF
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EFA6R Localizes to the PlasmaMembrane—Previous studies
indicated that EFA6A localizes to the PM to activate ARF6 (15).
Because EFA6R is structurally related to EFA6A and is expressed
in the plasma membrane fraction, we assessed whether EFA6R
also localizes to the PM in intact cells. For this purpose, GFP-
tagged EFA6Rwas expressed inHeLa or PC12 cells, and subcellu-
lar localizationwas analyzed by confocalmicroscopy. GFP-tagged
EFA6R was localized at the PM in both the cell lines tested. Like
GFP-EFA6R, FLAG-tagged EFA6R was also localized at the PM,
indicating that the largeGFP taghadnoeffect on subcellular local-
ization of EFA6R (Fig. 3). Furthermore, GFP-EFA6R showed the
PM localization even when expressed at very low levels (data not
shown). This together with the presence of endogenous EFA6R in
thePM fraction indicates that EFA6R localization to the PM is not
dependenton its expression levels.Toexamine the region(s) of the
protein required for targeting EFA6R to the PM, we generated a
series of deletion mutants of EFA6R with an N-terminal GFP
fusion and analyzed their subcellular localization in HeLa and
PC12 cells (Fig. 3). All of the fusion constructs containing both the
PH and CC domains were able to localize to the PM. In addition,
EFA6R lacking the CC domain (EFA6RCC) showed weak local-
ization to the PM, whereas EFA6R without the PH domain
(EFA6RPH) showed a diffuse cytoplasmic localization in both
the cell lines. These results demonstrate that the PH and CC
domains, but not the Sec7 domain, of EFA6R are required for its
localization to the PM. Moreover, these findings suggest that the
PH domain is necessary but not sufficient for the PM targeting of
EFA6R.
EFA6R Binds PIP2 through Its PH Domain—Because PH
domains are known to target proteins to the membrane by
binding to PIs, we assessed whether the PH domain of EFA6R
can bind to PIs and target EFA6R to the PM. To investigate
FIGURE 2.Analysis of EFA6Rprotein expression in various tissues, cell lines, and cell fractions. EFA6R protein expression in human tissues (A), cell lines (B), cell
fractions (D), and plasmamembrane proteins (E) was analyzed by immunoblotting (IB). HeLa cells were mechanically disrupted and fractionated into cytosolic and
membrane fractionsbyultracentrifugation.Theplasmamembraneproteinswere isolatedbydisruptingcell surface-biotinylatedHeLacellsand incubatingthe lysates
with streptavidinbeads. Thebeadswerewashedwithhigh salt andhighpHbuffers to obtain integral plasmamembraneproteins. Tissue (50gof protein/lane) and
whole cell lysates (100 g of protein/lane) or the cytosolic and the membrane fractions (20 g of protein/lane) were separated by SDS-PAGE, blotted onto PVDF
membrane, and probed with an anti-EFA6R antibody. HeLa whole cell lysate, the cytosolic andmembrane fractions, and the plasmamembrane proteins were also
immunoblotted for the presence of the cytosolic protein-tubulin and themembrane protein epidermal growth factor receptor (EGFR). The lysates of different cell
lines were probed with an anti--tubulin antibody to ensure equal loading. C, upper panel, EFA6R protein expression significantly reduced by siRNA-mediated
down-regulation of EFA6R. HeLa cells were transfectedwith negative (-ve) control siRNA, EFA6R siRNA1, EFA6 siRNA2, or ARF6 siRNA (positive control). After 3 days,
cells were lysed and immunoblotted (IB) with an anti-EFA6R rabbit polyclonal antibody, an anti-ARF6 mouse monoclonal antibody, or an anti--tubulin mouse
monoclonal antibody. Lower panel, corresponding quantitative data for the upper panel. ***, p 0.001; ns, not significant. Error bars represent S.D.
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FIGURE 3.EFA6R constructs and their subcellular localization.A, a schematic representation showing thedomain structure of the full-length EFA6R isoform
B and the various deletion constructs used in this study. B, the intracellular localization of EFA6R expression constructs. HeLa and PC12 cells transfected with
FLAG- or GFP-tagged EFA6R constructs were fixed, and FLAG-EFA6R-expressing cells were stained with an anti-FLAG antibody and visualized by confocal
microscopy. The images are representative of 90–95% of 190–200 transfected cells from three different cell preparations.
FIGURE4.EFA6Rbinds specifically toPI 4,5-P2 through thePHdomain in vitro.COS7cellswere transiently transfectedwithGFP,GFP-PLCPH, FLAG-EFA6R,
GFP-EFA6, or its deletion mutants. After 2 days, cells were lysed, and lysates were incubated with the indicated biotinylated PI lipids coupled to avidin beads
either in the presence (B) or absence (A and C) of water-soluble non-biotinylated PI lipids for 2 h at 4 °C. Protein that remained bound to the PI beads after
washing with 0.5% Nonidet P-40 was analyzed by immunoblotting (IB) with an anti-GFP or anti-FLAG antibody. 3-P, 3-phosphate. ***, p  0.001; ns, not
significant. Error bars represent S.D.
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whether EFA6R binds to PIs, we incubated the lysate of cells
expressing either GFP (negative control), GFP-PLCPH (posi-
tive control), GFP-EFA6R, or FLAG-EFA6R with avidin beads
alone (control beads) or coupled to biotinylated PI 3,4,5-tris-
phosphate, PI 3,4-P2, PI 3-phosphate, or PI 4,5-P2. Like GFP-
PLCPH, GFP-EFA6R and FLAG-EFA6R selectively bound to
the PI 4,5-P2-containing beads but not to the control beads or
the beads that contained other PIs (Fig. 4A). However, GFP
alone failed to bind any of the PIs tested under these conditions.
These data suggest that EFA6R specifically interacts with PI
4,5-P2.
We next analyzed the sensitivity of EFA6R binding with PI
4,5-P2 by conducting competition binding experiments (Fig.
4B). PI 3-phosphate, PI 3,4-P2, and PI 3,4,5-trisphosphate failed
to block EFA6R binding to PI 4,5-P2 beads at a very high con-
centration (10 M). However, PI 4,5-P2 blocked EFA6R inter-
action with PI 4,5-P2 beads. The concentration required to
block 50% of the binding (EC50) of PI 4,5-P2, PI 3,4-P2, PI 3,4,5-
trisphosphate, and PI 3-phosphate was calculated from the dis-
placement curve (Fig. 4B) as 1.1, 10, 10, and 10 M,
respectively. The ability of GFP-tagged EFA6R deletion
mutants to bind PI was further analyzed to determine which
domain is required for the binding to PI 4,5-P2 (Fig. 4C). Bind-
ing of theSec7 andCCmutants to PI 4,5-P2 beads was iden-
tical to that of the wild-type (WT) protein, whereas the PH
and PHmutants of EFA6R failed to bind PI 4,5-P2 beads under
the same conditions. These results indicate that EFA6R
requires the PHdomain to interactwith PI 4,5-P2.However, the
PH domain alone failed to bind PI 4,5-P2 beads, which could be
due to its improper folding. This is not uncommon because
many PI-binding PH domains such as Bruton tyrosine kinase
PH, cytohesin 1 PH, and cytohesin 2 PH domains require the
adjacent sequences for proper folding and binding to PIs
(36–38).
EFA6 Plasma Membrane Localization Is Dependent on Both
the PH and CC Domains—To determine whether binding of
EFA6R PH domain to PI 4,5-P2 is sufficient for the PM localiza-
tion of EFA6R in intact cells, HeLa cells expressing GFP-tagged
EFA6R, EFA6RPH, EFA6RCC, or PLCPH were stimulated
with ionomycin to cause the hydrolysis of PI 4,5-P2. Subcellular
localization of proteins was then analyzed by confocal micros-
copy (39). The loss of PI 4,5-P2 caused EFA6RCC and
PLCPH to relocate from the PM to the cytosol, whereas
EFA6R and EFA6RPH remained at the PM and cytosol,
respectively (Fig. 5). When cells were treated with the actin-
destabilizing chemical cytochalasin D, EFA6R showed weak
localization to the PM, a localization pattern similar to that of
EFA6RCC in untreated cells. Moreover, the loss of PI 4,5-P2
caused EFA6R to relocate from the PM to the cytosol in
cytochalasin D-treated cells. Together these data suggest that
EFA6R localizes to the PM by binding to PI 4,5-P2 directly
through its PH domain and that the localization is further sta-
bilized by the presence of an intact actin cytoskeleton and the
CC domain of EFA6R.
To provide direct support for a role of PI 4,5-P2 in EFA6R
targeting to the PM, we analyzed the effect of depletion of PI
4,5-P2 using a rapamycin-inducible PI 4,5-P2 5-phosphatase
system on the EFA6R localization (Fig. 6). The basis of this
system is that rapamycin induces translocation of the phospha-
tase domain of a PI 4,5-P2 5-phosphatase to the PM (through
FIGURE 5. Requirement of the PH and CC domains for membrane localization of EFA6R. A, upper panel, HeLa cells transfected with GFP-tagged EFA6R
constructs were treated with ionomycin. Lower panel, quantification of the ratio of plasma membrane EFA6R to total EFA6R by densitometric analysis. B, the
effect of ionomycin and cytochalasin D on subcellular localization is shown schematically. C, upper panel, HeLa cells transfected with GFP-EFA6R were treated
with ionomycin, cytochalasin D, or both and fixed, and subcellular localization was visualized by confocal microscopy. Lower panel, quantification of the ratio
of plasma membrane-localized EFA6R to total EFA6R by densitometric analysis. ***, p 0.001; ns, not significant. Error bars represent S.D.
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heterodimerization of the PM-targeted FRB domain of mam-
malian target of rapamycin with FKBP12 fused to the cytosolic
5-phosphatase) causing depletion of PI 4,5-P2 (Fig. 6A). This
system has been used previously to analyze the effect of PI
4,5-P2 depletion on the activity of TRPM8 andTRPV6 channels
(29, 40). Rapamycin induced translocation of the fusion protein
containing 5-phosphatase to the PM and relocation of PLCPH
(positive control) and EFA6RCC, but not EFA6R, from the
PM to the cytosol (Fig. 6B). However, rapamycin induced
EFA6R relocation to the cytosol in cytochalasin D-treated cells.
We used EFA6RPH localized to the cytosol in the presence or
absence of rapamycin as a negative control in the assay.
EFA6R Functions as an ARF6-specific GEF—To determine
whether or not EFA6R could function as an ARF GEF in intact
cells, we co-expressed either GFP-EFA6R, GFP-EFA6, or GFP
with eitherHA-ARF1 orHA-ARF6 in COS7 cells and subjected
the lysates to a pulldown assay with the VHS-GAT domain of
theARF effector GGA3 (theGST-GGA3PBD assay), which has
been shown previously to bind exclusively to the GTP-bound
form of ARFs (41). Western blotting with an anti-HA antibody
revealed expression of ARF1 or ARF6 in the lysates of all trans-
fected cells, whereas the GTP-bound form of ARF6 could only
be detected in cells transfected with ARF6 and either EFA6R or
EFA6, suggesting that EFA6R functions as a GEF selectively for
ARF6 (Fig. 7A). Consistent with this, endogenous ARF6-GTP
levels were reduced by siRNA-mediated knockdown of EFA6R
(Fig. 7B).
The ARF6 GEF Activity of EFA6R Is Dependent on the Sec7
Domain and the Plasma Membrane Localization—To resolve
whether or not the PH and CC domains are required for the
ARF6 GEF activity of EFA6R, the GST-GGA3 PBD pulldown
assay was carried out after co-transfection of HA-ARF6 with
various EFA6R deletion or point mutant constructs (Fig. 8A).
Wemade a point mutant of EFA6R tagged with GFP in which a
highly conserved glutamic acid was mutated to lysine (E134K)
to render the protein catalytically inactive. These catalytically
inactive mutants (E134K and Sec7) of EFA6R could not acti-
vate ARF6. The deletion mutants containing the functional
FIGURE 6. Effect of the depletion of PIP2 by rapamycin-induced membrane targeting of the 5-phosphatase on EFA6R subcellular localization. A,
schematic of the 5-phosphatase and FRB constructs and the mechanism of PIP2 hydrolysis (redrawn from Varnai et al. (29)). B, left panel, HeLa cells were
transfected with GFP-tagged EFA6R, EFA6RCC, EFA6RPH, or PLCPH along with the membrane-targeted FRB-CFP and the mRFP-FKBP-5-phosphatase
constructs. After 2 days, the cells were treated with cytochalasin D (CD), rapamycin, or both and fixed, and subcellular localization was visualized by confocal
microscopy. Right panel, quantification of the ratio of plasmamembrane EFA6R to total EFA6Rbydensitometric analysis. ***, p 0.001;ns, not significant. Error
bars represent S.D.
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Sec7 domain but lacking the PM targeting ability (Sec7 and
PH) also failed to activate ARF6. The EFA6RCC mutant,
which showed weak PM localization, activated ARF6 but to a
lesser extent when compared with EFA6R. When targeted to
the PM via addition of the CAAXmotif of K-Ras (which targets
the proteins to membranes through its farnesylation), the Sec7
domain alone (Sec7-CAAX) was sufficient to induce the ARF6
activation. However, the Sec7 domain with a catalytically inac-
tive point mutation (E156K) was unable to activate ARF6 fol-
lowing addition of the CAAX motif (Sec7E134K-CAAX). These
results indicated that EFA6R requires not only the catalytic
Sec7 domain but also PM localization through the PH and CC
domains to act as a GEF for ARF6.
We then sought to determine whether the reduction in the
ARF6 GEF activity of EFA6R by deletion of the CC domain was
due to a reduction in the PM localization. To this end, we stud-
ied the dose-dependent effect of EFA6R and EFA6RCC on
ARF6 activation. EFA6RPH, which does not activate ARF6,
was used as a negative control in the assay.We have shown that
the activation of ARF6 by EFA6R and EFA6RCC occurs in a
dose-dependent manner as increasing the amount of EFA6R/
EFA6RCC plasmid transfected into the cells with a constant
amount of ARF6 increased the amount of GTP-bound ARF6
detectable in the GST-GGA3 PBD pulldown (Fig. 8B, panel I).
At any given concentration, the amount of ARF6 activated by
EFA6RCC was lower than that activated by EFA6R when the
ARF6-GTP levels were normalized to the total EFA6R/
EFA6RCC protein expression. However, the amount of ARF6
activated by EFA6RCC was indistinguishable from that acti-
vated by EFA6R at all concentrations when the ARF6-GTP lev-
els were normalized to EFA6R/EFA6RCC protein expression
in themembrane fraction (Fig. 8B, panel II). These data suggest
that EFA6RCC is less active as an ARF6 GEF than EFA6R
because of its weak PM localization. These data also confirm
that EFA6R dissociation from the PM requires both PI 4,5-P2
depletion and actin destabilization.
EFA6R Co-localizes with ARF6 and Causes Reorganization of
the Actin Cytoskeleton—ARF6 relocates from endosomes to the
PM upon its activation and induces cortical actin formation at
the PM and concomitant loss of actin stress fibers (24). To
confirm that EFA6R can act as a GEF for ARF6 in vivo, we
examined the effect of EFA6R and its mutants on the subcellu-
lar localization of ARF6 in HeLa cells (Fig. 9). For this purpose,
we expressed GFP-tagged EFA6R or its point or deletion
mutants together with HA-ARF6 in HeLa cells and assessed
ARF6 localization by immunofluorescence using an anti-HA
antibody. As observed previously (24), a punctate staining pat-
tern was observed for ARF6 inHeLa cells (data not shown), and
its localization was unaltered when co-expressed with control
GFP. However, ARF6 was recruited to the PM in cells co-trans-
fected with GFP-EFA6R and HA-ARF6. EFA6RCC, which
showed weak PM localization, caused partial relocation of
ARF6 (35% of total) to the PM in cells co-transfected with
GFP-EFA6CC and HA-ARF6. Neither the catalytically inac-
tive mutant (E134K), which localized to the PM, nor the PH
and Sec7 deletionmutants, which did not localize to the PMbut
contained the active Sec7 domain of EFA6R, were able to
induce ARF6 redistribution to the PM in the transfected cells.
The PM-targeted Sec7-CAAX but not the Sec7E134K-CAAX
mutant of EFA6R was able to cause ARF6 redistribution to the
FIGURE 7. EFA6R specifically acts as a GEF for ARF6 in vivo. A, EFA6R activates ARF6, but not ARF1, in intact cells. COS7 cells were transfected with either
ARF1-HA or ARF6-HA and either GFP-EFA6R, GFP-EFA6A, or GFP. After 2 days, cells were serum-starved and lysed, and GTP-bound ARF proteins were precip-
itated from the lysateswithGST-GGA3PBDbeads.Upper panel, theGST-GGA3PBDpulldowns (activeGTP-boundARF) and lysates (total ARF)were analyzedby
immunoblotting (IB) with an anti-HA antibody. Lower panel, corresponding quantitative data for the upper panel. B, EFA6R down-regulation reduces endoge-
nous ARF6 activation. HeLa cells transfected with negative (-ve) control siRNA, EFA6R siRNA1, or EFA6 siRNA2 for 3 days were lysed, and the GTP-bound
endogenous ARF proteinswere precipitated from the lysateswith GST-GGA3 PBDbeads.Upper panel, the GST-GGA3 PBDpulldowns (active GTP-boundARF6)
and lysates (total ARF6 and EFA6R) were analyzed by immunoblotting (IB) with ARF6 and EFA6R antibodies. Lower panel, corresponding quantitative data for
the upper panel. **, p 0.01; ***, p 0.001; ns, not significant. Error bars represent S.D.
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PM. These data confirm that EFA6R requires both its GEF
activity and its association with the PM to activate ARF6.
We then examined the loss of actin stress fibers in cells
expressing GFP-tagged EFA6R or its mutants as a readout of
the ability of EFA6R to activate endogenous ARF6 (Fig. 9). The
actin network in the control GFP-transfected cells was similar
to that in untransfected cells (data not shown). GFP tagging had
no effect on the actin network. The loss of actin stress fiberswas
observed in cells expressing GFP-EFA6R, suggesting that
EFA6R induces loss of actin stress fibers. However, the E134K,
PH, and Sec7 mutants of EFA6R were unable to promote loss
of actin stress fibers in the transfected cells. The EFA6CC
mutant induced partial loss of actin stress fibers, whereas Sec7-
CAAX induced a loss of actin stress fibers, which was similar to
that of EFA6R, and the catalytically inactive Sec7E134K-CAAX
did not. This analysis also suggests that EFA6R-induced loss of
actin stress fibers was dependent on both the PM recruitment
and the GEF activity of EFA6R.
To confirm that EFA6R induces loss of actin stress fibers by
activating ARF6, we transfected HeLa cells with GFP-EFA6R
and the HA-tagged constitutively inactive mutant of ARF6
(ARF6T44N or ARF6T27N) or ARF1 (ARF1T31N) and analyzed
loss of actin stress fibers. As shown in Fig. 10, the constitutively
inactive mutants of ARF6, but not that of ARF1, reversed the
loss of actin stress fibers induced by EFA6R. This result indi-
cates that EFA6R causes the loss of actin stress fibers specifi-
cally through ARF6 activation.
DISCUSSION
ARFs regulate membrane trafficking at multiple sites within
the cell. Mammalian cells express six ARFs, over 15 ARF GEFs,
and 24ARFGTPase-activating proteins. Because theARFGEFs
and ARF GTPase-activating proteins outnumber ARFs, it has
been suggested that the ARF regulators contribute to the site-
specific regulation of ARFs. Therefore, understanding the ARF
specificities and functions of these regulators is extremely use-
ful in assessing spatiotemporal dynamics of ARF cellular func-
tions. However, the ARF substrate specificity, localization, and
functions are unknown for many of these regulators. In this
study, we have demonstrated the ability of EFA6R, a newmem-
FIGURE 8. EFA6R activates ARF6 in a functional Sec7 domain- andmembrane localization-dependent manner. A, EFA6R is dependent on its functional
Sec7 domain and membrane localization for the ARF6 GEF activity. Upper panel, EFA6R WT, the E134K mutant, and the deletion constructs were expressed
individually inCOS7cellswithARF6-HA, and theGEFactivity of EFA6RwasanalyzedbypulldownofGTP-boundARF6-HA. TheGST-GGA3PBDpulldowns (active
ARF6) and lysates (total ARF6) were analyzed by immunoblotting (IB) with an anti-HA antibody. Lower panel, corresponding quantitative data for the upper
panel. B, concentration dependent activation of ARF6 by EFA6R or its mutants (EFA6RCC and EFA6RPH). COS7 cells were transfected with ARF6-HA and
various amounts of GFP-EFA6R (WT), GFP-EFA6RCC (CC), or GFP-EFA6RPH (PH) plasmids. After 2 days, cells were serum-starved for 2 h and lysed,
ARF6-GTP was precipitated from lysates with GST-GGA3 PBD beads, and the precipitates were then immunoblotted with anti-HA antibody. The transfected
cells were also homogenized and centrifuged to obtain the cytosol and membrane fractions. The cell lysates and membrane fractions were immunoblotted
with anti-HA and anti-GFP antibodies to determine expression levels of total ARF6 and EFA6R or its deletions mutants, respectively. Densitometric analysis of
the ARF6-GTP is shown after normalization to the expression of EFA6 or its mutants in the total (panel I) or in themembrane fraction (panel II). **, p 0.01; ***,
p 0.001; ns, not significant. Error bars represent S.D.
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ber of the EFA6 subfamily of ARF6 GEFs, to localize to the PM
by binding PIP2 through the PH domain, to increase cellular
levels of ARF6-GTP, and to stimulate reorganization of the
actin cytoskeleton.
Because ARFs 1–5 are mainly found at the Golgi, whereas
ARF6 localizes to the PM, it has been suggested that the sub-
strate specificity of ARF GEFs is likely to be conferred by their
subcellular localization. We have shown that EFA6R is consti-
tutively localized to the PM, suggesting that it may act as a
specific GEF for ARF6 in vivo. This hypothesis is also suggested
by the binding of EFA6R to PI 4,5-P2 as PI 4,5-P2 has previously
been implicated in the localization of EFA6A and several other
proteins to the PM (42, 43). The requirement of both the CC
and PH domains in membrane recruitment was assessed by
using CC and PH deletion mutants of EFA6R and the com-
pounds ionomycin and cytochalasin D. The loss of the CC
domain or actin destabilization by cytochalasin D treatment
abolished the PM localization of EFA6R upon depletion of PIP2
levels, indicating that the CC domain and intact actin cytoskel-
eton are important for a secondary site of association between
EFA6R and the actin cytoskeleton/PM. Furthermore, EFA6R
lacking the PH domain localized to the cytosol. Together these
data suggest that binding of the PH domain to PIP2 is required
for EFA6R localization to the PM, which is further stabilized by
a secondary site of association between EFA6R and the actin
cytoskeleton and/or plasma membrane. EFA6A in contrast has
been shown to localize to the PMbybinding bothPIP2 and actin
through the PH domain (39). However, EFA6A has also been
shown to bind -actinin, an actin-binding protein, through its
C-terminal CC domain in dendritic spines (44). Unlike EFA6A,
we found that EFA6R did not interact directly with F-actin in
FIGURE9.Effectof EFA6Rand itsmutantsonARF6 localizationand lossof
actin stress fibers. HeLa cells were transiently transfected with GFP, GFP-
EFA6R, or its mutants with or without ARF6-HA. After 2 days, the cells were
serum-starved, fixed with paraformaldehyde, immunostained with an
anti-HA antibody or rhodamine-conjugated phalloidin (for actin), and
imaged using a confocal microscope. The images are representative of
85–90% of 90–110 transfected cells from three different cell preparations.
FIGURE10.Theconstitutively inactivemutantofARF6,ARF6T27NorARF6T44N,preventspotentiationofactinstress fiber lossbyEFA6R.Top, a schematic
representation showing the ARF mutants that locked in the inactive GDP-bound form. Bottom, HeLa cells were transiently transfected with either GFP or
GFP-EFA6Rwith ARF6T27N-HA, ARF6T44N-HA, or ARF1T31N-HA. After 2 days, the cells were serum-starved, fixedwith paraformaldehyde, immunostainedwith an
anti-HA antibody and rhodamine-conjugated phalloidin (for actin), and imaged using a confocal microscope. The images are representative of 85–90% of
75–90 transfected cells from three different cell preparations.
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vitro (data not shown). Because the CC domain of EFA6R is
highly homologous to that of EFA6A, it is tempting to speculate
that EFA6R may also bind to actin cytoskeleton via -actinin.
We confirmed the selectivity of EFA6R for ARF6 by co-ex-
pressing the proteins in an in vivo system and specifically pre-
cipitating out GTP-bound ARF from cell lysates. To do this, we
took advantage of the interaction between ARFs and a family of
ARF effectors, theGGAproteins, which bind toARFs in aGTP-
dependent manner (45), by expressing the ARF-binding VHS-
GAT domain as a GST fusion protein. ARF6-GTP levels were
increased upon co-expression with either EFA6R or EFA6A, a
previously characterized GEF for ARF6 (15), whereas ARF1-
GTP levels did not increase when expressed with either EFA6R
or EFA6A but are increased when co-expressed with the ARF1
exchange factor BIG1 (46, 47). Furthermore, ARF6-GTP levels
were decreased upon knockdown of EFA6R expression. These
data suggest that EFA6R acts as an ARF6-specific GEF in vivo
and that this activity occurs in a concentration-dependent
manner as increasing the amount of EFA6R plasmid used for
transfection of the cells increased the amount of ARF6-GTP in
the lysates.
To determine the role of different domains of EFA6R on the
activation of ARF6, we co-expressed ARF6 with various dele-
tion constructs of EFA6R and repeated the GST-GGA3 PBD
assay. Results indicate that the CC and PH domains are both
required for membrane targeting because the Sec7 domain
alone when artificially targeted to the PMwith the CAAXmotif
from Ras was sufficient to stimulate ARF6-GTP binding to a
level comparable with that of the full-length protein. We also
found that expression of active but not catalytically inactive
(E134K) EFA6R caused translocation of ARF6 from an intracel-
lular, presumably endocytic, compartment to the PM, suggest-
ing that ARF6 translocation is dependent on its bound
nucleotide.
To investigate the functional relevance of EFA6R-mediated
ARF6 activity, we examined the effect of overexpression of var-
ious EFA6R constructs on the morphology of the actin cyto-
skeleton. In agreement with previous studies suggesting that
increased levels of ARF6-GTP cause rearrangements of actin
(15, 23, 24, 47), we found that expression of EFA6R or its Sec7
domain targeted to the membrane by addition of the CAAX
motif caused a loss of actin stress fibers. The expression of
either the catalytically inactive EFA6RE134K or any of the dele-
tion mutants with abolished GEF activity toward ARF6 did not
induce loss of actin stress fibers, suggesting that EFA6R causes
a loss of actin stress fibers by activating ARF6. Consistent with
this, EFA6R-induced actin rearrangements were reversed by
the constitutively inactive mutant of ARF6 but not that of
ARF1. Furthermore, EFA6R knockdown affected endogenous
ARF6 activation. As mentioned in the Introduction, there is
accumulating evidence for differential EFA6R expression in
malignant diseases such as ovarian cancer (7, 14, 19–22), and
experiments are now in progress to determine the role of
EFA6R in ovarian cancer. In this regard, the findings reported
in this study will assist further investigation of ARF6GEF activ-
ity-dependent and -independent roles of EFA6R in ovarian
cancer.
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